赛升药业
(300485)
| 流通市值：20.89亿 | | | 总市值：36.75亿 |
| 流通股本：2.74亿 | | | 总股本：4.82亿 |
| 报告期 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 476,569,581.71 | 393,823,690.35 | 272,037,764.09 | 132,698,154.36 |
| 营业收入 | 476,569,581.71 | 393,823,690.35 | 272,037,764.09 | 132,698,154.36 |
| 二、营业总成本 | 517,647,765.37 | 373,630,956.3 | 259,863,119.34 | 130,399,239.51 |
| 营业成本 | 140,939,314.33 | 112,700,745.37 | 76,426,298.34 | 38,075,260.12 |
| 税金及附加 | 7,398,782.55 | 4,683,693.52 | 4,005,262.69 | 877,461.99 |
| 销售费用 | 230,427,810.21 | 163,157,081.44 | 111,488,579.76 | 54,080,490.78 |
| 管理费用 | 62,197,453.23 | 39,513,816.01 | 25,899,497.53 | 10,640,234.86 |
| 研发费用 | 77,733,166.44 | 54,287,924.94 | 42,384,348.73 | 26,803,792.38 |
| 财务费用 | -1,048,761.39 | -712,304.98 | -340,867.71 | -78,000.62 |
| 其中:利息收入 | 1,103,652.1 | 758,348.27 | 383,348.95 | 86,712.45 |
| 加:公允价值变动收益 | 100,266,690.82 | 124,730,596.58 | 167,086,773 | -7,154,180 |
| 加:投资收益 | 59,806,708.02 | 71,152,662.08 | 99,152,282.28 | 674,100.99 |
| 资产处置收益 | 2,537.73 | - | - | - |
| 资产减值损失(新) | 0 | - | - | - |
| 信用减值损失(新) | 1,646,900.73 | -216,145.19 | -980,688.61 | 6,519,406.37 |
| 其他收益 | 1,091,528.42 | 200,844.31 | 79,375.31 | 75,239.83 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 121,736,182.06 | 216,060,691.83 | 277,512,386.73 | 2,413,482.04 |
| 加:营业外收入 | 470,016.57 | 31,026.73 | 28,378.83 | 24,764 |
| 减:营业外支出 | 43,169.02 | 18,183.8 | 994.35 | 94.35 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 122,163,029.61 | 216,073,534.76 | 277,539,771.21 | 2,438,151.69 |
| 减:所得税费用 | 25,755,290.03 | 22,787,052.88 | 27,994,882.82 | 2,031,684.42 |
| 六、净利润 | 96,407,739.58 | 193,286,481.88 | 249,544,888.39 | 406,467.27 |
| 持续经营净利润 | 96,407,739.58 | 193,286,481.88 | 249,544,888.39 | 406,467.27 |
| 归属于母公司股东的净利润 | 102,917,838.16 | 196,525,841.12 | 251,662,971.29 | 823,935.6 |
| 少数股东损益 | -6,510,098.58 | -3,239,359.24 | -2,118,082.9 | -417,468.33 |
| (一)基本每股收益 | 0.21 | 0.41 | 0.52 | 0 |
| (二)稀释每股收益 | 0.21 | 0.41 | 0.52 | 0 |
| 八、其他综合收益 | 591,669.48 | 1,077,506.8 | 1,307,822.96 | -464,521.99 |
| 归属于母公司股东的其他综合收益 | 591,669.48 | 1,077,506.8 | 1,307,822.96 | -464,521.99 |
| 九、综合收益总额 | 96,999,409.06 | 194,363,988.68 | 250,852,711.35 | -58,054.72 |
| 归属于母公司股东的综合收益总额 | 103,509,507.64 | 197,603,347.92 | 252,970,794.25 | 359,413.61 |
| 归属于少数股东的综合收益总额 | -6,510,098.58 | -3,239,359.24 | -2,118,082.9 | -417,468.33 |
| 公告日期 | 2024-04-10 | 2023-10-27 | 2023-08-25 | 2023-04-26 |
| 审计意见(境内) | 标准无保留意见 | | | |